Abstract | OBJECTIVE: METHODS: On day 0, virgin female Sprague-Dawley rats (age, 55 d) were given DMBA (20 mg/rat). Sixty-day timed-release pellets containing 25 mg MPA were implanted into the rats on day 30. Curcumin was administered daily at a rate of 200 mg kg-1 day-1 from days 26 to 50, and animals were killed on day 52 (n = 15-19 per group). RESULTS: Treatment with curcumin delayed the first appearance of MPA-accelerated tumors by 7 days, decreased tumor incidence by the end of the experiment, and reduced tumor multiplicity in DMBA-induced MPA-accelerated tumors. Curcumin also prevented many of the gross histological changes seen in the MPA-treated mammary gland. Immunohistochemical analyses of mammary tumors showed that curcumin decreased MPA-induced VEGF induction in hyperplastic lesions, although it did not affect the levels of estrogen and progesterone receptors. CONCLUSIONS: We suggest that curcumin be tested as a dietary chemopreventive agent in women already exposed to MPA, in an effort to decrease or delay the risk of breast cancer associated with combined HT.
|
Authors | Candace E Carroll, Indira Benakanakere, Cynthia Besch-Williford, Mark R Ellersieck, Salman M Hyder |
Journal | Menopause (New York, N.Y.)
(Menopause)
2010 Jan-Feb
Vol. 17
Issue 1
Pg. 178-84
ISSN: 1530-0374 [Electronic] United States |
PMID | 19629015
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Vascular Endothelial Growth Factor A
- vascular endothelial growth factor A, rat
- 9,10-Dimethyl-1,2-benzanthracene
- Medroxyprogesterone Acetate
- Curcumin
|
Topics |
- 9,10-Dimethyl-1,2-benzanthracene
- Animals
- Antineoplastic Agents
(pharmacology)
- Curcumin
(pharmacology)
- Dietary Supplements
- Female
- Mammary Neoplasms, Experimental
(chemically induced, metabolism, pathology, prevention & control)
- Medroxyprogesterone Acetate
- Rats
- Rats, Sprague-Dawley
- Vascular Endothelial Growth Factor A
(metabolism)
|